2 Kommentare / 0 neu
25.10.2012 11:44
Bild des Benutzers Dominique.
Kommentare: 21


Company description


Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing, and other topical indications. In addition, Oxygen Biotherapeutics has also have under development Vitavent, an oxygen exchange fluid for facilitating the treatment of lung conditions, and it has out-licensed its rights to a biosensor implant product that uses an enzyme process for measuring the glucose level in subcutaneous fluid.



25.10.2012 11:50
Bild des Benutzers Dominique.
Kommentare: 21

Kann dieses Asset zurzeit risikoreichen Anlegern nur Empfahlen ! 


Talsohle vor wenigen Tagen erreicht, liegt im Moment in einem Absoluten Trendkanal. 


Fundamental sieht bei Oxygen Biotherapeutics auch alles sehr gut aus.


09-10-2012 11:00  DJ Oxygen Biotherptics Files 8K - Listing Notice >OXBT 



Oxygen Biotherapeutics Inc. (OXBT) filed a Form 8K - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - with the U.S Securities and Exchange Commission on October 03, 2012.


On October 3, 2012, Oxygen Biotherapeutics, Inc., (the "Company") received a notification letter from the Listing Qualifications Department of The NASDAQ Stock Market ("NASDAQ") indicating that, for the last 30 consecutive business days, the bid price for the Company's common stock has closed below the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market under Marketplace Rule 5550(a)(2).

In accordance with Marketplace Rule 5550(a)(2), the Company has 180 calendar days, or until April 1, 2013, to regain compliance with the minimum $1.00 price per share requirement. To regain compliance, anytime before April 1, 2013, the bid price of the Company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. NASDAQ's notification letter has no effect on the listing of the Company's common stock at this time.

On April 1, 2013, if the Company meets The NASDAQ Capital Market initial listing criteria set forth in Marketplace Rule 5505, except for the minimum bid price requirement, it may be provided with an additional 180 calendar day compliance period to demonstrate compliance. If the Company is not eligible for an additional compliance period at that time, NASDAQ will provide the Company with written notification that its common stock will be delisted. Upon such notice, the Company may appeal the NASDAQ Staff's determination to a NASDAQ Listing Qualifications Panel, pursuant to the procedures set forth in the applicable NASDAQ Marketplace Rules. There can be no assurance that, if the Company appeals the NASDAQ Staff's determination, such appeal would be successful.

The Company is currently evaluating its alternatives to resolve this listing deficiency.


The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/34956/000135448812005193/oxbt_8k.htm


Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/34956/000135448812005193/00013544...


Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.


Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

October 09, 2012 05:00 ET (09:00 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.